RecruitingNot ApplicableNCT07292246

A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)


Sponsor

Vasileios Kalles

Enrollment

15 participants

Start Date

Sep 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to learn whether a handheld robotic device, called the HandX, can help surgeons safely perform a minimally invasive nipple-sparing mastectomy. This type of mastectomy uses a small incision at the side of the breast to remove breast tissue while keeping the skin and nipple in place. The goal is to lower scarring, improve comfort, and support good cosmetic results after surgery. Participants in this study will already be planning to have a therapeutic or preventive mastectomy with immediate implant-based reconstruction. All surgeries are done at Mediterraneo Hospital in Greece. During the operation, surgeons use the HandX device to assist with the endoscopic dissection. Researchers will collect information about how long the surgery takes, whether the planned approach can be completed without switching to open surgery, and whether any surgical complications occur. They will also check healing, infection, and implant-related problems for up to 365 days after surgery. Participants will complete the BREAST-Q questionnaire before surgery and at several times after surgery to share their views on comfort, well-being, and cosmetic outcomes. About 15 participants will take part. The results will help researchers understand whether this approach is practical and safe, and whether it should be studied further in a larger trial.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates the feasibility of using a robotic-assisted endoscopic technique (HandX) for mastectomy (breast removal surgery) in women with early breast cancer, DCIS, or those at high genetic risk, as an alternative to traditional open surgery. **You may be eligible if...** - You are a woman aged 18 or older - You are scheduled for a therapeutic or risk-reducing mastectomy for early-stage invasive breast cancer (Stage I–II), DCIS, or because you carry a BRCA or similar gene mutation - Your breast size is cup A to C and expected implant volume is less than 550cc - You are in good general health (ECOG/WHO performance status below 2) **You may NOT be eligible if...** - Your breast size or ptosis (droopiness) exceeds the criteria for this technique - You have conditions that make you a poor surgical candidate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREEndoscopic nipple sparing mastectomy

A minimally invasive nipple-sparing mastectomy performed through a single lateral mammary fold incision using endoscopic visualization and CO₂ insufflation. Breast tissue is dissected from the skin envelope and nipple-areola complex, and immediate implant-based reconstruction is performed according to standard practice. The HandX device is used for articulating endoscopic dissection.

DEVICEHandX endoscopic instrument

A handheld articulating endoscopic instrument used to assist with endoscopic dissection during nipple-sparing mastectomy. The HandX device provides wrist-like articulation, motion scaling, and ergonomic control during minimally invasive surgery.


Locations(1)

Mediterraneo Hospital

Glyfada, Attica, Greece

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07292246


Related Trials